NCT01130909View on ClinicalTrials.gov

A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765

PHASE1TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Healthy
Interventions
DRUG

AZD6765

75 mg

DRUG

AZD6765

150 mg

DRUG

Ketamine

0.5 mg/kg

DRUG

Placebo

125 mL sterile NaCl 0.9%

Trial Locations (1)

Unknown

Research Site, Rouffach

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY